Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 20/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.39 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5202970 | 0.83 | — | — | |
| SCHEMBL528253 | 0.83 | — | — | |
| SCHEMBL444005 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL33649 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Hydrochloric Acid SCHEMBL22720671 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Bromide SCHEMBL5203587 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Bromide SCHEMBL3545017 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Hydrochloric Acid SCHEMBL22720839 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Hydrochloric Acid SCHEMBL19347669 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 | |
| Hydrochloric Acid SCHEMBL30144741 | 0.81 | CRBN (0.44) | CRBNDDB1IKZF3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245210-A1 | THALIDOMIDE ANALOGS | The Government of the United States of America, as represented by the Secretary of | 2011-10-06 | — | — | US | claimed |
| JP-2007505922-A | — | — | 2007-03-15 | — | — | JP | claimed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | claimed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | claimed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | claimed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | claimed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| CN-116419922-B | Method for selectively synthesizing 3,6' -dithiopomalidomide from pomalidomide | 艾维斯生物株式会社 | 2025-05-02 | — | — | CN | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240174630-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | SHUTTLE PARMACEUTICALS, LLC | 2024-05-30 | — | — | US | disclosed |
| CN-1867331-B | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2010-05-26 | — | — | CN | disclosed |
| EP-1964842-A1 | 5H-THIENO [3,4-c]PYRROLE-4, 6-DIONE DERIVATIVES AGAINST CELL RELEASING TUMOR NECROSIS FACTOR | Tian Jin Hemay Bio-Tech Co., Ltd. (CN) | 2008-09-03 | — | — | EP | disclosed |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2008-07-24 | — | — | US | disclosed |
| CN-1867331-A | Thalidomide analogs as TNF-alpha modulators | US GOV HEALTH & HUMAN SERV (US) | 2006-11-22 | — | — | CN | disclosed |
| US-20060211728-A1 | Thalidomide analogs | P2D INC. | 2006-09-21 | — | — | US | disclosed |
| EP-1663223-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005028436-A2 | THALIDOMIDE ANALOGS AS TNF-ALPHA MODULATORS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-20060211728-A1 | Thalidomide analogs | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
| US-20240174630-A1 | SELECTIVE HISTONE DEACETYLASE INHIBITORS FOR THE TREATMENT OF HUMAN DISEASE | HDAC1, HDAC2, HDAC5 | CRBN 378/4885DDB1 1100/4885IKZF3 216/4885 |
| US-20110245210-A1 | THALIDOMIDE ANALOGS | TNF, TNFRSF1A, PGF | CRBN 321/4885DDB1 953/4885IKZF3 854/4885 |
| US-20080176900-A1 | 5H-THIOENO(3,4-c)PYRROLE-4,6-DIONE DERIVATIVES AND THEIR USE AS TUMOR NECROSIS FACTOR INHIBITORS | TNF, TNFRSF1A, CD40 | CRBN 938/4885DDB1 1951/4885IKZF3 1039/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | CRBN 187/4885DDB1 1267/4885IKZF3 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.